Alkermes Gets FDA Approval for Schizophrenia Treatment Aristada

October 07 11:03 2015

Alkermes (ALKS), a biopharmaceutical company, said Tuesday the U.S. Food and Drug Administration has approved ARISTADA extended-release injectable suspension to treat schizophrenia.

The company is preparing to launch the drug immediately.

Shares were 7.9% lower in midday trade, below the midpoint of the 52-week range of $38.49 – $75.17.

Companies: Alkermes plc
Price: 54.91 Price Change: -4.86 Percent Change: -8.13

Alkermes Gets FDA Approval for Schizophrenia Treatment Aristada
 
 
  Article "tagged" as:
  Categories:
 
write a comment

0 Comments

No Comments Yet!

You can be the one to start a conversation.

Add a Comment

CAPTCHA image
*